We performed a randomized, double-blind, placebo-controlled, single-center study in 60 subjects who were not taking drugs that could affect metabolic and vascular functions. Subjects were randomized into either a KRG (4.5 g/d) group or a placebo group for a 12-week study. We collected anthropometric measurements, blood for laboratory testing, and brachial-anklepulse wave velocity (baPWV) at the initial (week 0) and final (week 12) visits.
RESULTS:
A total of 48 subjects successfully completed the study protocol. Oral administration of KRG did not significantly affectblood pressure, oxidative or inflammatory markers, or baPWV.